Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 28, 2014
Pharmacy Choice - Pharmacy News - November 28, 2014

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
11/27/14 - LifeTech Sci's product approved as innovative medical device [ET Net News (China)]
LifeTech Scientific Corporation said it. has recently obtained the final approval from the Center for Medical Device Evaluation of. the China Food and Drug Administration and its iron-based bioresorbable drug-eluting.
11/27/14 - SQI DIAGNOSTICS Receives FDA Clearance for its Ig-plex Celiac DGP Panel for Sale in the United States
By a News Reporter-Staff News Editor at Politics& Government Week-- SQI Diagnostics Inc. announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States. "We are very excited to have received FDA clearance," said Andrew Morris, CEO, SQI Di
11/27/14 - Valeant gets FDA approval for ONEXTON gel to treat acne vulgaris [EMBIN (Emerging Markets Business Information News]
Valeant Pharmaceuticals International has received approval from the Food and Drug Administration for ONEXTON Gel, 1.2%/ 3.75%, for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. We are very pleased that the FDA has approved this new dual action medication that gives physicians and patients a new option for th
11/25/14 - Philips receives FDA 510(k) clearance for IQon Spectral CT
--Reinforcing its commitment to enabling confident diagnosis through innovation, Royal Philips today announced 510 clearance from the U.S. Food and Drug Administration for its IQon Spectral CT, presenting an entirely new approach to spectral imaging. This first-of-its kind technology adds a new dimension to Computed Tomography imaging, delivering..
11/25/14 - Valeant Pharmaceuticals Announces FDA Approval Of ONEXTONâ?¢ Gel For The Treatment Of Acne Vulgaris
--Valeant Pharmaceuticals International, Inc. announced today that it has received approval from the Food and Drug Administration for ONEXTONâ?¢ Gel, 1.2%/ 3.75%, for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new dual action medication that gives physic
11/25/14 - Vascular Solutions Receives 510(k) Clearance for Gel-Block 10x Embolization Product
Vascular Solutions, Inc. today announced that it has received 510 clearance from the U.S. Food and Drug Administration for Gel-Block 10 x embolization pledgets for use in the treatment of hypervascular tumors and arteriovenous malformations. Vascular Solutions is launching the product in the U.S. this week. The Gel-Block 10 x version builds on Vasc

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415